New schizophrenia drug shows promise in Long-Term safety trial
NCT ID NCT07459647
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new drug called ML-007C-MA for adults with schizophrenia. The goal is to see if it is safe and works well over a full year. About 500 people who have recently been in a related study or are new to the trial will take the drug twice daily. Researchers will track side effects and how well the drug controls symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ML-007C-MA (a combination drug taken twice daily)
What this could lead to
If successful, this could provide a new long-term treatment option for schizophrenia that is safe and effective for daily use.
What could go wrong
This is an early phase 2 open-label study, so results are not definitive. Side effects or lack of effectiveness may still emerge, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site
RECRUITINGLemon Grove, California, 91945, United States
-
Clinical Site
RECRUITINGMiami Lakes, Florida, 33016, United States
-
Clinical Site
RECRUITINGChicago, Illinois, 60640, United States
-
Clinical Site
RECRUITINGStaten Island, New York, 10314, United States
-
Clinical Site
RECRUITINGDeSoto, Texas, 75115, United States